MITOMYCIN and OFF LABEL USE

Overview

OFF LABEL USE is the #1 most commonly reported adverse reaction for MITOMYCIN, manufactured by UroGen Pharma, Inc.. There are 372 FDA adverse event reports linking MITOMYCIN to OFF LABEL USE. This represents approximately 8.1% of all 4,566 adverse event reports for this drug.

Patients taking MITOMYCIN who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OFF LABEL USE is moderately reported among MITOMYCIN users, representing a notable but not dominant share of adverse events.

Other Side Effects of MITOMYCIN

In addition to off label use, the following adverse reactions have been reported for MITOMYCIN:

• NAUSEA — 159 reports
• DIARRHOEA — 146 reports
• FATIGUE — 116 reports
• THROMBOCYTOPENIA — 108 reports
• DRUG INEFFECTIVE — 106 reports
• NEUTROPENIA — 105 reports
• RASH — 104 reports
• VOMITING — 104 reports
• PANCYTOPENIA — 100 reports
• DISEASE PROGRESSION — 95 reports

Other Drugs Associated with OFF LABEL USE

The following drugs have also been linked to off label use in FDA adverse event reports:

Does MITOMYCIN cause OFF LABEL USE?

OFF LABEL USE has been reported as an adverse event in 372 FDA reports for MITOMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OFF LABEL USE with MITOMYCIN?

OFF LABEL USE accounts for approximately 8.1% of all adverse event reports for MITOMYCIN, making it one of the most commonly reported side effect.

What should I do if I experience OFF LABEL USE while taking MITOMYCIN?

If you experience off label use while taking MITOMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages